|
Post by otherottawaguy on Feb 25, 2015 13:48:01 GMT -5
Waiting to see a drop of 9M during the August period. Hope it about $15 a share when we do so that BofA feels some pain.
OOG
|
|
|
Post by mnholdem on Feb 25, 2015 14:26:09 GMT -5
That would be shweeeeet!
|
|
|
Post by mannmade on Feb 26, 2015 12:38:59 GMT -5
MannKind: ‘Encouraged By Early Feedback’ on Afrezza Launch By Ben Levisohn Jefferies’ Shaunak Deepak found MannKind‘s (MNKD) early take on the Afrezza launch encouraging: On its earnings call, MannKind was straightforward about expectations that the Afrezza launch would not be explosive, but rather slow and steady. That said, we were encouraged by the early feedback and the fact that Sanofi (SNY) asked to increase the volume of Afrezza samples, as demand has been higher than anticipated. MannKind noted reimbursement discussions were ongoing and that while some plans placed Afrezza on Tier 3, other plans were requiring prior authorization. We believe that the Afrezza Patient Savings Card may help ease the financial burden for many patients, while these arrangements are being sorted out. Looking ahead to 2Q, MannKind is on track for approval of 12-Unit dose of Afrezza, offering a larger single- dose option to more advanced patients, and bringing additional manufacturing capacity online, enabling production of three times as many cartridges as today. While we see these as positive steps, we continue to believe that the Afrezza launch will take time, as physicians will need to change the way they use mealtime insulin to fully realize Afrezza’s potential in insulin-naïve patients. Deepak rates MannKind a Buy, with a $10 price target. With MannKind shares trading off 1.7% at $6.79 today, that leaves 47% of upside to Deepak’s target. Sanofi has fallen 3% to $48.91.
|
|
|
Post by mannmade on Feb 26, 2015 12:42:20 GMT -5
Yahoo FInance
Jefferies Expects Exciting 2015 For MannKind Benzinga By Nicholas Donato 1 hour ago Shaving Rebuilt for Your Best Shave Yet Gillette® Sponsor With the initial Afrezza launch recently commencing, MannKind Corporation (NASDAQ: MNKD) has already seen encouraging sales steps despite management stating that sales would initially be "slow and steady." Early feedback from Sanofi SA (ADR) (NYSE: SNY) is that demand has been higher than expected and need more samples.
Despite these positive notes, Jefferies analyst Shaunak Deepak noted, "we continue to believe that the Afrezza launch will take time, as physicians will need to change the way they use mealtime insulin to fully realize Afrezza's potential in insulin-naïve patients."
An inhalable insulin product provides an attractive, yet new alternative compared to other methods such as injection or pumps.
Deepak values MannKind entirely on the Afrezza product, which is proprietary due to its Technosphere Technology. MannKind has targeted other medical therapeutic areas to leverage its Technosphere patent such as pulmonary disease, pain and oncology.
MannKind recently implemented a Afrezza Patient Savings Card, which should help ease financial costs for users. Deepak views this customer reimbursement arrangement plan, along with identifying other possible product pipelines as reasons to maintain MannKind's Buy rating and $10 price target.
Shares of MannKind recently traded down 1.7 percent at $6.80, implying Deepak sees 45 percent potential upside to his own price target.
Latest Ratings for MNKD Date Firm Action From To Oct 2014 Goldman Sachs Initiates Coverage on Neutral Aug 2014 Jefferies Initiates Coverage on Buy Jul 2014 MLV Downgrades Buy Hold View More Analyst Ratings for MNKD View the Latest Analyst Ratings
See more from Benzinga
L Brands -
|
|
|
Post by liane on Feb 27, 2015 6:10:18 GMT -5
www.bidnessetc.com/35630-heres-why-griffin-securities-is-bullish-on-mannkind-corporation/Here’s Why Griffin Securities Is Bullish On MannKind Corporation Griffin Securities reiterates rating and price target on MannKind stock, following Afrezza debut By: Larry Darrell Published: Feb 25, 2015 at 3:03 pm EST Griffin securities reiterated a Buy rating and price target of $16.25 on MannKind Corporation (NASDAQ:MNKD) stock. The decision was taken on the basis of the introduction of inhalable insulin called Afrezza, which helps diabetic patients (particularly adults) improve blood sugar control. Pharmaceutical Sector analyst, Keith Markey, believes that it is too early to predict Afrezza sales, as it has been around two weeks since its introduction. The initial demand is coming from diabetic patients and everyone else who participated in the clinical trials, as well as others who already knew about its attributes well before its debut. By mid-2015, Afrezza sales can be better estimated, as then the general public and the retailers will be fully aware of the new product and its attributes, which will be assisted by new strategies that are yet to be implemented, and supplemented with high marketing promotional activities. Mr. Markey informed investors that Mannkind is expected to increase its production line in order to multiply its insulin production capacity by the end of this quarter The sell-side firm also believes that the research and development (R&D) pipeline will be re-filled once again, as MannKind plans to develop technosphere formulations through active pharmaceutical ingredients in three areas: pulmonary disease, pain, and cancer supportive care. Mannkind performed in-line with analyst’ expectation at the end of financial year 2014 (FY14); the pharmaceutical company plans to refinance its debt through loans or bonds by the end of August, in order to pay back its previous debt. The stock is up by 3.13%, trading at $6.93 as of 2:01 AM EST. Out of the 12 analysts that cover MannKind stock, four rate it a Buy and seven recommend a Hold. The 12-month price target forecasted by the analysts for the stock is $9.04.
|
|
|
Post by xoxoxoxo on Mar 2, 2015 21:23:07 GMT -5
|
|
|
Post by mannmade on Mar 2, 2015 21:24:53 GMT -5
Has anyone actually seen the GS release on this?
|
|
|
Post by savzak on Mar 2, 2015 21:28:35 GMT -5
Has anyone actually seen the GS release on this? I would like to see it. I'm imagining a perfectly transparent pretext. But I'd like confirmation.
|
|
|
Post by xoxoxoxo on Mar 2, 2015 21:30:02 GMT -5
Has anyone actually seen the GS release on this? I would like to see it. I'm imagining a perfectly transparent pretext. But I'd like confirmation. I'm pretty confident in it being true. Not because I see it reposted all over Twitter, but because I added 50 contracts of leaps earlier this week.
|
|
|
Post by gwb on Mar 2, 2015 21:44:31 GMT -5
Has anyone actually seen the GS release on this? I would like to see it. I'm imagining a perfectly transparent pretext. But I'd like confirmation. Just The Fly on wall for now .
www.americanbankingnews.com/2015/03/02/mannkind-stock-rating-lowered-by-goldman-sachs-mnkd/
MannKind Stock Rating Lowered by Goldman Sachs (MNKD)
March 2nd, 2015 • 0 comments • Filed Under • by ABMN Staff Share on StockTwits
MannKind logoMannKind (NASDAQ:MNKD) was downgraded by stock analysts at Goldman Sachs from a “neutral” rating to a “sell” rating in a report issued on Monday, TheFlyOnTheWall.com reports.
MannKind (NASDAQ:MNKD) traded up 1.84% during mid-day trading on Monday, hitting $6.64. The stock had a trading volume of 6,091,980 shares. MannKind has a one year low of $3.80 and a one year high of $11.48. The stock’s 50-day moving average is $6.4 and its 200-day moving average is $6.10. The company’s market cap is $2.633 billion.
MannKind (NASDAQ:MNKD) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). During the same quarter in the previous year, the company posted ($0.16) earnings per share. On average, analysts predict that MannKind will post $-0.33 earnings per share for the current fiscal year.
A number of other firms have also recently commented on MNKD. Analysts at Zacks reiterated a “neutral” rating and set a $7.25 price target on shares of MannKind in a research note on Thursday. Analysts at MLV & Co set a $7.00 price target on shares of MannKind and gave the company a “hold” rating in a research note on Wednesday, February 25th. Analysts at Piper Jaffray set a $7.00 price target on shares of MannKind and gave the company a “hold” rating in a research note on Wednesday, February 25th. Finally, analysts at JMP Securities reiterated a “hold” rating on shares of MannKind in a research note on Wednesday, February 25th. One analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $9.03.
The Fly On The Wall
|
|
|
Post by harrythekingisindahouse on Mar 2, 2015 22:01:57 GMT -5
They are no dummies (a lot of other things) but they seem to do this all the time. Downgrade, buy, upgrade, sell that is GS game. GS increased their holdings of MNKD over 175% in Dec, yes before the "launch" but I'm not falling for this. I'm holding onto my shares and if it dips I'm loading up more. GLTA.
|
|
|
Post by whosmitchconnor on Mar 3, 2015 1:01:32 GMT -5
They are no dummies (a lot of other things) but they seem to do this all the time. Downgrade, buy, upgrade, sell that is GS game. GS increased their holdings of MNKD over 175% in Dec, yes before the "launch" but I'm not falling for this. I'm holding onto my shares and if it dips I'm loading up more. GLTA. So they are after one last buying opportunity at low levels. I'll be looking for an increase in position size on the institutional holdings report for 1st quarter now.
|
|
|
Post by savzak on Mar 3, 2015 6:32:41 GMT -5
I realize that Goldman's downgrade to "sell" will trigger the knee jerk reaction they're planning. Many will blindly react. Many more will pile on "for the trade".
But I can't help concluding that the reasons they give for the downgrade matters this time much more than before. The list of reasons for such a castrating downgrade to $3 is very short now. I suspect their reasoning may not pass the smell test.
The point is that the soundness of their thesis is important now that Afrezza is actually being sold in the marketplace. If it rings hollow and not credible, Goldman's intended effect may be very short lived as bargain hunters and covering shorts step in to take advantage of the situation.
If anyone can share Goldman's thesis, I'd appreciate it.
|
|
|
Post by garrett on Mar 3, 2015 6:40:15 GMT -5
It's obvious. Drive the price down so their friends who are short can get out and they (GS) can buy more.
|
|
|
Post by mannmade on Mar 3, 2015 10:43:59 GMT -5
www.forbes.com/sites/johnlamattina/2015/03/03/if-you-want-to-make-a-good-drug-great-cost-must-be-factored-in/?utm_campaign=yahootix&partner=yahootixIf You 'Want To Make A Good Drug Great' Cost Must Be Factored In In a recent Fortune article, author Laura Lorenzetti asked “Is the future of pharma about making good drugs great?” Her article focuses on companies that are developing new delivery platforms for drugs already on the market, but whose performance can be enhanced by novel technologies. The drivers for taking such an approach can be enticing. As a biotech analyst told her, “By taking a drug that’s already approved, you’re trimming down the approval process. It’s a lower risk product because the FDA’s already liked it.” Importantly, the original drug has already cleared animal toxicology, human efficacy, and safety studies – major causes of attrition for a new molecular entity. One of the “game-changing innovations” cited by Lorenzetti is Afrezza, an inhaled version of insulin marketed by MannKind and Sanofi. The attraction of an inhalable form of insulin is that diabetics would avoid injecting themselves with this life-saving hormone. However, this isn’t an entirely new concept. Pfizer marketed an inhaled insulin product, Exubera, a decade ago, and for a variety of reasons it failed so badly that Pfizer took a $2.6 billion pretax loss. MannKind and Sanofi believe, however, that Afrezza is a superior product and that may prove to be the case. But, while the FDA has approved Afrezza, the long-term human safety implications of delivering a growth hormone like insulin to the lung still need to be proven and the manufacturer will be studying this over the coming years. Just because insulin can be injected safely over the course of a diabetic’s life doesn’t guarantee that inhaling insulin will be just as safe. But beyond the safety challenges that a new manner of delivering a drug could impose, more important is the overall impact of the cost of the new delivery system. In her article, Lorenzetti highlights a biotech company called OptiNose, which is focused on the nasal delivery of drugs. OptiNose has developed a plastic device that uses one’s own breath to close off one’s nasal cavity and deliver a drug very deeply into the nose. In partnership with Avanir, the first drug likely to reach the market with the OptiNose technology is AVP-825 for migraine, currently under FDA review. AVP-825 utilizes the well-known migraine drug, sumatriptan, in OptiNose’s device. The hope for AVP-825 is that, by virtue of its method of delivery, it will provide more rapid migraine relief than sumatriptan provides orally or when inhaled. AVP-825 may well deliver on its promise. However, the challenge will be how much quicker will the pain relief be and if this is significant enough of a difference over generic sumatriptan to justify the anticipated premium price that will be expected for a new product like this. The price of a nine tablet (100mg) pack of sumatriptan pills costs less than $20. The cost of a generic nasal spray version of sumatriptan (six 20mg doses) costs less than $130. Avanir has not set a price for AVP-825, but it is likely to be much higher than this. How will payers react? Rather than “risk – benefit”, payers focus on the cost value of the benefit. My guess is that initially AVP-825 will be limited to those patients for whom sumatriptan and other cheaper migraine drugs are poorly effective. For people whose migraines are reasonably controlled, ample justification as to why the more rapid pain relief of AVP-825 will be needed to justify coverage – and even then a high co-pay might be required. There is no doubt that the reformulation or “reinvention” of an old generic drug has built-in advantages in maneuvering though the R&D process. However, even after FDA approval, the commercial hurdle of convincing payers that the new entity merits reimbursement is still a challenge, particularly when generic alternatives already exist. There are no easy options in bringing a new medicine to market – old or new.
|
|